Table 2. Enrichment of KEGG pathway annotations amongst the co-expression-predicted ECCN interacting genes.
| KEGG ID | Pathway | p-value | FDR |
|---|---|---|---|
| hsa03013 | RNA transport | 3.51E-40 | 8.00E-38 |
| hsa03040 | Spliceosome | 6.64E-40 | 1.50E-37 |
| hsa04110 | Cell cycle | 7.95E-23 | 1.80E-20 |
| hsa03008 | Ribosome biogenesis in eukaryotes | 6.98E-21 | 1.60E-18 |
| hsa04120 | Ubiquitin mediated proteolysis | 4.01E-16 | 9.00E-14 |
| hsa03018 | RNA degradation | 1.95E-14 | 4.40E-12 |
| hsa03030 | DNA replication | 6.08E-14 | 1.40E-11 |
| hsa03015 | mRNA surveillance pathway | 8.00E-12 | 1.80E-09 |
| hsa04141 | Protein processing in endoplasmic reticulum | 2.52E-11 | 5.60E-09 |
| hsa04310 | Wnt signalling pathway | 1.26E-10 | 2.80E-08 |
| hsa05200 | Pathways in cancer | 3.19E-09 | 7.00E-07 |
| hsa04740 | Olfactory transduction | 6.69E-09 | 1.50E-06 |
| hsa03430 | Mismatch repair | 8.92E-09 | 1.90E-06 |
| hsa00230 | Purine metabolism | 1.24E-08 | 2.70E-06 |
| hsa00240 | Pyrimidine metabolism | 1.24E-08 | 2.70E-06 |
| hsa04010 | MAPK signalling pathway | 1.84E-08 | 3.90E-06 |
| hsa03420 | Nucleotide excision repair | 6.15E-08 | 1.30E-05 |
| hsa05220 | Chronic myeloid leukemia | 2.60E-07 | 5.50E-05 |
| hsa04722 | Neurotrophin signalling pathway | 2.94E-07 | 6.20E-05 |
| hsa04144 | Endocytosis | 5.12E-07 | 1.10E-04 |
| hsa04114 | Oocyte meiosis | 7.00E-07 | 1.50E-04 |
| hsa05210 | Colorectal cancer | 7.63E-07 | 1.60E-04 |
| hsa04660 | T cell receptor signalling pathway | 1.16E-06 | 2.40E-04 |
| hsa05213 | Endometrial cancer | 2.74E-06 | 5.70E-04 |
| hsa04914 | Progesterone-mediated oocyte maturation | 3.32E-06 | 6.80E-04 |
| hsa04720 | Long-term potentiation | 3.78E-06 | 7.70E-04 |
| hsa05160 | Hepatitis C | 1.04E-05 | 2.10E-03 |
| hsa04810 | Regulation of actin cytoskeleton | 1.17E-05 | 2.40E-03 |
| hsa04012 | ErbB signalling pathway | 1.38E-05 | 2.80E-03 |
| hsa05216 | Thyroid cancer | 1.42E-05 | 2.80E-03 |
| hsa04910 | Insulin signalling pathway | 1.45E-05 | 2.90E-03 |
| hsa05211 | Renal cell carcinoma | 1.76E-05 | 3.50E-03 |
| hsa03050 | Proteasome | 1.95E-05 | 3.80E-03 |
| hsa05223 | Non-small cell lung cancer | 2.30E-05 | 4.50E-03 |
| hsa03450 | Non-homologous end-joining | 5.12E-05 | 1.00E-02 |
Only terms with q < 0.01 (false discovery rate after Benjamini-Hochberg) are shown.